ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Defining the Position of [177Lu]Lu-PSMA Radioligand Therapy in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer: A Meta-analysis of Clinical Trials

  • 期刊论文

  • 发表日期：

    2024年11月29日

查看全文
  • Chiara Ciccarese,
  • Matteo Bauckneht,
  • Luca Zagaria,
  • Giuseppe Fornarini,
  • Viria Beccia,
  • Francesco Lanfranchi,
  • Germano Perotti,
  • Giada Pinterpe,
  • Fortuna Migliaccio,
  • Giampaolo Tortora,
  • Lucia Leccisotti,
  • Gianmario Sambuceti,
  • Alessandro Giordano,
  • Orazio Caffo,
  • Roberto Iacovelli

摘要

Background

In recent years, theranostics has become a promising approach for treating metastatic castration-resistant prostate cancer (mCRPC), with trials investigating targeted radioligand therapy, particularly using prostate-specific membrane antigen labeled with lutetium-177 ([177Lu]Lu-PSMA). The proper position of [177Lu]Lu-PSMA in the therapeutic algorithm of mCRPC is yet to be identified.

Design, Setting, and Participants

We conducted a systematic review and meta-analysis of phase II/III randomized controlled trials to assess the efficacy of [177Lu]Lu-PSMA in treating mCRPC. Study endpoints included radiographic progression-free survival (rPFS), prostate-specific antigen-PFS, objective response rate, and overall survival.

Outcome Measurements and Statistical Analysis

Data were extracted according to the PRISMA statement. Summary hazard ratios (HRs) were calculated using random- or fixed-effects models. Statistical analyses were performed with RevMan software (v.5.2.3).

Results

[177Lu]Lu-PSMA reduced the risk of rPFS (HR 0.55; 95% confidence interval [CI] 0.43–0.71; p < 0.00001) and prostate-specific antigen-PFS (HR 0.53; 95% CI 0.41–0.67; p < 0.00001), and improved the objective response rate compared with control therapies (response rate 3.55; 95% CI 1.91–6.60; p < 0.0001), whereas no significant cumulative effect on overall survival was documented (HR 0.92; 95% CI 0.65–1.31; p = 0.63). Notably, in a dedicated subanalysis, comparable effects on rPFS were observed when [177Lu]Lu-PSMA was compared with active therapy.

Conclusion

[177Lu]Lu-PSMA has a favorable impact on the radiographic and biochemical control of mCRPC and represents a potential treatment in a scenario where other valuable options are available. Further efforts are required to identify clinical and molecular markers necessary for proper patient stratification.